Najat Khan

Najat Khan

current Chief Executive Officer and PresidentatRecursion Pharmaceuticals· In proxies 2023–2025

Pay in FY2025-42% from the year before · Recursion Pharmaceuticals stock -39.5% the same year

Najat Khan was paid $5.3M in FY2025 (Dec), down 42%. Recursion Pharmaceuticals stock fell 39.5% that year.

Pay$100 in the stock at the end of FY23 → $41
Pay is from the Summary Compensation Table of each Recursion Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Recursion PharmaceuticalsPublic company · 3 yr
    • current Chief Executive Officer and President2023 – Present · 3 yrStock in role -39%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?